Follow Fresenius Medical Care AG & Co. KGaA to never miss an important update.
Bernstein nudged its target up from $25.50 but kept its rating at Market Perform, which means they expect the stock to perform in line with the broader market. Truist Financial took the opposite view, lowering its target to $25.00. The average target among analysts currently sits at $24.00, which is slightly above the current price.
Source: Bernstein
The company reported earnings of $0.66 per share, which was higher than the $0.62 analysts expected. This profit growth was driven by a massive restructuring program that is closing underperforming clinics and cutting costs. It also benefited from higher reimbursement rates, which are the payments the company receives from insurance and government programs for each dialysis treatment.
However, the number of patients receiving treatments in the U.S. fell again this quarter. This is a persistent concern because fewer treatments mean less long-term revenue. While the stock fell as investors focused on these volume issues, management is sticking to its full-year goals, betting that efficiency gains and new technology like the 5008X dialysis machine will keep profits growing even if the patient base does not.
The U.S. government announced plans to impose heavy tariffs on imported generic medicines starting in 2028. These are taxes on imported goods that usually make them more expensive than those made locally. Because Fresenius Medical Care already has extensive manufacturing operations inside the U.S., it may face fewer costs than competitors who rely more on imports.
This could give the company a pricing advantage in the coming years. While the full impact is still far off, it suggests the company's existing infrastructure is a hedge against changing trade policies that might hurt other healthcare providers.
Analysts adjusted their price targets following the company's recent quarterly earnings report. Most experts are cautious, with 14 of 21 rating the stock as neutral and the average target price sitting at roughly the current share price.
Management consistently sets a low bar and clears it with small profit beats, showing they have a firm handle on their costs even as the number of patients they treat shrinks.
| Expectation | |
|---|---|
| EPS | $0.61 |
| Revenue | $5.71B |
Follow Fresenius Medical Care AG & Co. KGaA to get the latest and most important updates.
Follow FMS